Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease

Inclusion Criteria: * Male or female \>= 28 years of age * Confirmed diagnosis of cystic fibrosis * Forced Expiratory Volume in 1 second (FEV1) \>= 40% predicted * Clinically stable * Ability to reproduce spirometry * Ability to understand and sign the informed consent Exclusion Criteria: * Use of an investigational agent within 4-week period prior to Visit 1 * Chronic daily use of ibuprofen or other NSAIDS * Chronic daily use of insulin,oral diabetic agents or oral hypoglycemic agents * History of hypersensitivity to beta agonists * History of hypersensitivity to glitazones * Oxygen saturation\<92% * Pregnant, breastfeeding or unwilling to practice acceptable birth control * History of hemoptysis \>30cc per episode within 30 days prior to Visit 1 * Significant history of hepatic, cardiovascular, renal,neurologic, hematologic or peptic ulcer disease * Serum Glutamic-Oxaloacetic Transaminase (SGOT)/(Serum Glutamic Pyruvic Transaminase (SGPT) \>3 times the upper limit of normal at screening, documented biliary cirrhosis,or portal hypertension * Creatinine \> 1.8 mg/dL at screening * Inability to swallow pills * Presence or abnormality that in the opinion of the investigator would compromise the safety or the quality of the data * Subjects who have routinely taken ibuprofen or other NSAIDS; prednisone or other systemic corticosteroids, or insulin, or oral diabetic agents within 4 weeks prior to visit 1 or who have taken these medications as needed within 72 hours prior to visit one will be excluded